ATAI LIFE SCIENCES BV.
9VC.XETRA | Research and experimental development on natural sciences and engineering
ATAI Life Sciences BV is a biopharmaceutical company focused on developing innovative treatments for mental health disorders. They invest in and incubate companies working on a variety of therapeutic approaches, including psychedelic compounds and other pharmaceutical interventions. Their activities...Show More
Better Health for All
10
ATAI Life Sciences N.V. is a clinical-stage biopharmaceutical company
1
entirely focused on developing therapies for mental health disorders, which represent significant unmet medical needs.
2
Its mission is to transform patient outcomes by developing rapid-acting, durable, and convenient mental health treatments for conditions like PTSD, treatment-resistant depression (TRD), social anxiety disorder (SAD), and cognitive impairment associated with schizophrenia (CIAS).
3
The company's entire business is devoted to health improvement, with a pipeline of potential new treatments.
4
Positive topline results from a Phase 2b study of BPL-003 in TRD demonstrated rapid, robust, and durable antidepressant effects with a single dose.
5
For BPL-003, over 99% of treatment-emergent adverse events were mild or moderate, with no drug-related serious adverse events or suicide-related safety signals.
6
As a clinical-stage company, it has minimal revenue, and none is derived from products with negative health outcomes.
7
The company launched atai Impact, a philanthropic program, initially funded by 1% of its IPO gross proceeds and founders' contributions, aiming to support equal access to mental health support.
8
It also has a Volunteer Paid Time Off Policy equal to 1% of employees’ time to foster neuro-innovators.
9
Clinical trials, such as the Phase 1 study for EMP-01, have received ethics approvals from The Health and Disability Ethics Committees (HDEC).
10
Fair Money & Economic Opportunity
0
ATAI Life Sciences BV is a biopharmaceutical company focused on mental health treatments, not a financial institution. Therefore, KPIs related to financial services, lending, fees, customer financial data, and wealth-building outcomes are not applicable. The company does not offer lending or deposit services to consumers, nor does it generate revenue from high-cost financial products or penalty fees. It does not have a loan/insurance book, manage customer finance data, or operate as a regulated lender. The company also does not provide debt products to consumers or operate financial service access points. While the company does reinvest profits into research and development, as evidenced by $11.3 million in R&D expenses for the three months ended March 31, 2025,
1
there is no evidence of profit reinvestment specifically in community finance or profit-sharing with underserved communities as defined by the rubric. Similarly, there is no evidence of financial literacy programs or product simplicity for financial products.
Fair Pay & Worker Respect
40
The company received an overall employee rating of 4.7 out of 5 stars based on 38 reviews, indicating a high level of satisfaction.
1
Additionally, 95% of employees would recommend working at the company to a friend, and 94% reported a positive business outlook.
2
Employees rated compensation and benefits at 4.4 out of 5 stars.
3
In early March 2023, the company laid off approximately 30% of its staff, primarily affecting general, administration, and non-clinical development roles.
4
As of January 1, 2025, the CEO's annual base salary is $629,200 with a 55% bonus target, and as of December 3, 2024, the COO's initial annual base salary is $440,000 with a 40% bonus target.
5
Fair Trade & Ethical Sourcing
0
No information regarding fair trade or ethical sourcing, including specific metrics such as fair trade certification share, audit frequency, forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend, was found in the provided articles for ATAI Life Sciences BV.
1
Honest & Fair Business
-40
ATAI Life Sciences provides a confidential and anonymous financial concern hotline for complaints regarding accounting, internal accounting controls, or auditing matters, with options for email, secure web form, or secure hotline.
1
A 14-16 digit code is provided for message status tracking and potential follow-up by the Audit Committee.
2
The company's executive separation agreements explicitly state that the right to report violations of federal law or regulation, including under Sarbanes-Oxley, is not released.
3
As a Dutch-seated company
4
with 54 employees,
5
it is subject to the Dutch Whistleblower Protection Act, which requires confirmation of receipt within seven days and informing of follow-up steps within three months, and prohibits prejudice against reporting persons.
6
The company's Code of Conduct forms the foundation of its policies and practices, including compliance with the Foreign Corrupt Practices Act (FCPA).
7
However, there is no evidence of training frequency or effectiveness metrics for this policy. There is no evidence of independent verification of ethical claims or compliance.
Kind to Animals
-50
The company conducts animal testing for drug discovery programs, including studies on novel compounds in rodent models and preclinical randomized controlled trials involving 143 female rats and 154 male rats.
1
A press release explicitly states the use of animal models for product testing.
2
The company has a commitment to the 3Rs (replacement, reduction, and refinement) in animal research and a humane endpoints policy to minimize pain and discomfort.
3
Methodologies, procedures, and equipment are refined to decrease stress on animals.
4
The company has a C.A.R.E. program in place, with every employee pledging to support it, and uses EU-compliant group housing for NHPs.
5
It is actively engaged in the exploration of New Approach Methodologies (NAMs) in toxicology and risk assessment, and attentive to their growing role in shaping the future of toxicology.
6
However, there is no specific percentage of R&D budget allocated to animal-free technologies, only that it supports development of non-animal methods.
No War, No Weapons
-70
ATAI Life Sciences N.V. is involved in activities related to controversial weapons and small arms.
1
This indicates a lack of codified ethical red lines banning these categories. Furthermore, this involvement means the company cannot demonstrate zero exposure to controversial or banned weapons.
Planet-Friendly Business
0
No specific, concrete data points or relevant information regarding ATAI Life Sciences BV's environmental performance, targets, or initiatives were found across the provided articles.
1
Therefore, no KPIs could be scored against the 'Planet-Friendly Business' rubric.
Respect for Cultures & Communities
0
No cultural appropriation incidents involving ATAI Life Sciences BV have been reported in the provided articles.
1
While the broader psychedelic industry faces ethical considerations regarding cultural appropriation, no specific incidents are attributed to the company.
2
Similarly, there is no direct evidence of a formal cultural impact assessment protocol, FPIC processes, community governance inclusion, cultural preservation investment, grievance mechanisms, language inclusivity, cultural incident response framework, cultural sensitivity training completion, cultural site protection actions, documented social license to operate, charitable giving to cultural heritage organizations, or community fund allocations specifically from ATAI's operations.
3
The articles discuss these concepts in the context of the industry or related research projects, but not as direct actions or policies of ATAI Life Sciences BV.
Safe & Smart Tech
10
As of February 12, 2025, the company has stated that there have been no security breaches, incidents, unauthorized access, or disclosure relating to its IT systems and data.
1
Furthermore, it has not received written notice of any violation of its privacy obligations in the past three years.
2
The company represents that it has implemented and maintained commercially reasonable controls, policies, procedures, and technological safeguards designed to protect the integrity and security of its IT systems and data, consistent with applicable industry standards.
3
It also states that it is in compliance with all applicable laws and contractual obligations related to the privacy and security of its IT systems and data.
4
Its privacy policy references compliance with regulations such as GDPR and CCPA.
5
Zero Waste & Sustainable Products
0
No specific, quantifiable evidence was found regarding ATAI Life Sciences BV's performance across any of the Zero Waste & Sustainable Products KPIs. The provided articles discuss general industry trends
1
, regulatory frameworks
2
, and case studies from other entities or suppliers
3
, but do not offer concrete data points directly attributable to ATAI Life Sciences BV's waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.